<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01183234</url>
  </required_header>
  <id_info>
    <org_study_id>SPD544-101</org_study_id>
    <nct_id>NCT01183234</nct_id>
  </id_info>
  <brief_title>SPD544 High Strength Bioequivalence Study</brief_title>
  <official_title>Phase 1,Randomized,Open-Label,Two Period Single Dose Crossover Bioequivalence Study of Two Capsule Strengths of SPD544 In Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess bioequivalence of 2 capsule strengths.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomised, open-label, two-period, single dose, crossover bioequivalence
      study in healthy subjects under fasting conditions to assess bioequivalence of 1 x 60 mg
      capsule methylphenidate compared to 2 x 30 mg capsules methylphenidate. Pharmacokinetics and
      safety will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Steady-state Plasma Concentration-time Curve (AUC 0-t) for Methylphenidate Hydrochloride (MPH) Using Two Different Formulations (Equasym XL and Metadate CD)</measure>
    <time_frame>predose and 0.5, 1.0, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20 and 24 hours post-dose</time_frame>
    <description>AUC 0-t is the area under the plasma concentration versus time curve from time 0 to the time of last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for MPH Using Two Different Formulations (Equasym XL and Metadate CD)</measure>
    <time_frame>predose and 0.5, 1.0, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20 and 24 hours post-dose</time_frame>
    <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Plasma Concentration (Tmax) for MPH Using Two Different Formulations (Equasym XL and Metadate CD)</measure>
    <time_frame>predose and 0.5, 1.0, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20 and 24 hours post-dose</time_frame>
    <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>SPD544 (Equasym XL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylphenidate hydrochloride (Metadate CD )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPD544</intervention_name>
    <description>two 30mg capsules, single oral dose</description>
    <arm_group_label>SPD544 (Equasym XL)</arm_group_label>
    <other_name>Equasym XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate hydrochloride</intervention_name>
    <description>one 60mg capsule, single oral dose</description>
    <arm_group_label>Methylphenidate hydrochloride (Metadate CD )</arm_group_label>
    <other_name>Metadate CD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy subjects, aged 18-55 years inclusive at the time of consent.

          2. Subject must be willing to comply with applicable contraceptive requirements of the
             protocol and be:

               -  Male, or

               -  Non-pregnant, non-lactating female who must be &gt;90 days post-partum or
                  nulliparous.

          3. Body Mass Index (BMI) between 18.5 and 30.0kg/mÂ² inclusive. This inclusion criterion
             will only be assessed at the Screening visit.

          4. Satisfactory medical assessment with no clinically significant or relevant
             abnormalities in medical history, physical examination, vital signs, ECG, and clinical
             laboratory evaluation (haematology, biochemistry, urinalysis) as assessed by the
             Investigator.

          5. Ability to provide written, personally signed and dated informed consent to
             participate in the study.

          6. An understanding, ability and willingness to fully comply with study procedures and
             restrictions.

          7. Ability to swallow all investigational medicinal products (IMPs).

        Exclusion criteria:

          1. Current or recurrent disease (e.g., cardiovascular, renal, liver, gastrointestinal,
             malignancy or other conditions) that could affect the action, absorption, or
             disposition of the IMPs, or could affect clinical or laboratory assessments.

          2. Current or relevant history of physical or psychiatric illness, any medical disorder
             that may require treatment or make the subject unlikely to fully comply with the
             requirements of the study or complete the study, or any condition that presents undue
             risk from the IMPs or study procedures.

          3. Current use of any medication (including prescription, over-the-counter [OTC], herbal,
             or homeopathic preparations) with the exception of hormone replacement therapy or
             hormonal contraceptives and/or an occasional dose of nonsteroidal anti-inflammatory
             (NSAID), or paracetamol (current use is defined as use within 14 days of first dose of
             IMP).

          4. History of hypertension or a resting sitting systolic blood pressure &gt;139mmHg or
             diastolic blood pressure &gt;89mmHg.

          5. History of seizure (other than infantile febrile seizures), any tic disorder, or a
             current diagnosis and/or family history of Tourette's Disorder.

          6. Known history of symptomatic cardiovascular disease, advanced arteriosclerosis,
             structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities,
             coronary artery disease, transient ischaemic attack or stroke, or other serious
             cardiac problems that may place them at increased vulnerability to the sympathomimetic
             effects of a stimulant drug.

          7. Family history of sudden cardiac death or ventricular arrhythmia.

          8. Known cerebrovascular disorders such as cerebral aneurysm, vascular abnormalities
             including vasculitis or history of stroke.

          9. Diagnosis of glaucoma.

         10. Diagnosis of phaeochromocytoma.

         11. Current abnormal thyroid function, as defined as abnormal screening thyroid
             stimulating hormone (TSH) and thyroxine (T4).

         12. Current marked anxiety, tension and/or agitation.

         13. History of alcohol or other substance abuse within the last year.

         14. A positive screen for alcohol or drugs of abuse at Screening or Day -1 of Treatment
             Period 1.

         15. Male subjects who consume more than 3 units of alcohol per day. Female subjects who
             consume more than 2 units of alcohol per day.

         16. A positive human immunodeficiency virus (HIV) antibody screen, Hepatitis B surface
             antigen (HBsAg), or Hepatitis C virus (HCV) antibody screen.

         17. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing
             products in any form (e.g., gum, patch) within 30 days prior to the Screening visit.

         18. Routine consumption of more than 300mg of caffeine per day or subjects who experience
             caffeine withdrawal headaches or have a history of caffeine withdrawal headaches.

         19. Donation of blood or blood products (e.g., plasma or platelets) within 90 days prior
             to the first dose of IMP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Muna Albayaty</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paraxel International</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paraxel International</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <results_first_submitted>July 27, 2011</results_first_submitted>
  <results_first_submitted_qc>July 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2011</results_first_posted>
  <last_update_submitted>August 31, 2011</last_update_submitted>
  <last_update_submitted_qc>August 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Equasym XL (SPD544) First, Then Metadate CD</title>
          <description>Subjects received a single oral dose of 60 mg of Equasym XL (given as two 30 mg capsules), then a 7-day washout period, then subjects received a single oral dose of 60 mg of Metadate CD (given as one 60 mg capsule)</description>
        </group>
        <group group_id="P2">
          <title>Metadate CD First, Then Equasym XL</title>
          <description>Subjects received a single oral dose of 60 mg of Metadate CD (given as one 60 mg capsule), then a 7-day washout period, then subjects received a single oral dose of 60 mg of Equasym XL (given as two 30 mg capsules)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Equasym XL First, Then Metadate CD</title>
          <description>Subjects received a single oral dose of 60 mg of Equasym XL (SPD544, Methylphenidate HCl given as two 30 mg capsules), then a 7-day washout period, then subjects received a single oral dose of 60 mg of Metadate CD (Methylphenidate HCl given as one 60 mg capsule)</description>
        </group>
        <group group_id="B2">
          <title>Metadate CD First, Then Equasym XL</title>
          <description>Subjects received a single oral dose of 60 mg of Metadate CD (Methylphenidate HCl given as one 60 mg capsule), then a 7-day washout period, then subjects received a single oral dose of 60 mg of Equasym XL (SPD544, Methylphenidate HCl given as two 30 mg capsules)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="10.12"/>
                    <measurement group_id="B2" value="29.5" spread="8.61"/>
                    <measurement group_id="B3" value="30.1" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Steady-state Plasma Concentration-time Curve (AUC 0-t) for Methylphenidate Hydrochloride (MPH) Using Two Different Formulations (Equasym XL and Metadate CD)</title>
        <description>AUC 0-t is the area under the plasma concentration versus time curve from time 0 to the time of last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
        <time_frame>predose and 0.5, 1.0, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20 and 24 hours post-dose</time_frame>
        <population>Pharmacokinetic analysis set (PK) defined as all subjects in the safety analysis set who had evaluable plasma concentration-time profiles for MPH through 24 hours post-dosing in both treatment periods. Subjects who vomited or experienced significant diarrhea between dosing and 10 hours post-dose were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Equasym XL</title>
            <description>Subjects received a single oral dose of 60 mg of Equasym XL (Methylphenidate HCl given as two 30 mg capsules)</description>
          </group>
          <group group_id="O2">
            <title>Metadate CD</title>
            <description>Subjects received a single oral dose of 60 mg of Metadate CD (Methylphenidate HCl given as one 60 mg capsule)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Steady-state Plasma Concentration-time Curve (AUC 0-t) for Methylphenidate Hydrochloride (MPH) Using Two Different Formulations (Equasym XL and Metadate CD)</title>
          <description>AUC 0-t is the area under the plasma concentration versus time curve from time 0 to the time of last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
          <population>Pharmacokinetic analysis set (PK) defined as all subjects in the safety analysis set who had evaluable plasma concentration-time profiles for MPH through 24 hours post-dosing in both treatment periods. Subjects who vomited or experienced significant diarrhea between dosing and 10 hours post-dose were excluded.</population>
          <units>ng*h/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133" lower_limit="122" upper_limit="145"/>
                    <measurement group_id="O2" value="127" lower_limit="116" upper_limit="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Point estimates and 90% confidence intervals for the ratio of the treatment regimen means were provided by back-transformation on to the linear scale and were assessed against the currently accepted bioequivalence criteria for log-transformed data (0.80, 1.25).</non_inferiority_desc>
            <param_type>Ratio of geometric LS means</param_type>
            <param_value>0.953</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.915</ci_lower_limit>
            <ci_upper_limit>0.993</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) for MPH Using Two Different Formulations (Equasym XL and Metadate CD)</title>
        <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
        <time_frame>predose and 0.5, 1.0, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20 and 24 hours post-dose</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Equasym XL</title>
            <description>Subjects received a single oral dose of 60 mg of Equasym XL (Methylphenidate HCl given as two 30 mg capsules)</description>
          </group>
          <group group_id="O2">
            <title>Metadate CD</title>
            <description>Subjects received a single oral dose of 60 mg of Metadate CD (Methylphenidate HCl given as one 60 mg capsule)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) for MPH Using Two Different Formulations (Equasym XL and Metadate CD)</title>
          <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
          <population>PK set</population>
          <units>ng/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="13.8" upper_limit="16.1"/>
                    <measurement group_id="O2" value="14.7" lower_limit="13.7" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Point estimates and 90% confidence intervals for the ratio of the treatment regimen means were provided by back-transformation on to the linear scale and were assessed against the currently accepted bioequivalence criteria for log-transformed data (0.80, 1.25).</non_inferiority_desc>
            <param_type>Ratio of geometric LS means</param_type>
            <param_value>0.988</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.931</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Plasma Concentration (Tmax) for MPH Using Two Different Formulations (Equasym XL and Metadate CD)</title>
        <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
        <time_frame>predose and 0.5, 1.0, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20 and 24 hours post-dose</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Equasym XL</title>
            <description>Subjects received a single oral dose of 60 mg of Equasym XL (Methylphenidate HCl given as two 30 mg capsules)</description>
          </group>
          <group group_id="O2">
            <title>Metadate CD</title>
            <description>Subjects received a single oral dose of 60 mg of Metadate CD (Methylphenidate HCl given as one 60 mg capsule)</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Plasma Concentration (Tmax) for MPH Using Two Different Formulations (Equasym XL and Metadate CD)</title>
          <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
          <population>PK set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.983" upper_limit="5.15"/>
                    <measurement group_id="O2" value="5.0" lower_limit="0.967" upper_limit="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.150</ci_lower_limit>
            <ci_upper_limit>0.492</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Analysis Set consisted of subjects who took at least 1 dose of investigational product and had at least 1 post-dose safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Equasym XL</title>
          <description>Subjects received a single oral dose of 60 mg of Equasym XL (Methylphenidate HCl given as two 30 mg capsules)</description>
        </group>
        <group group_id="E2">
          <title>Metadate CD</title>
          <description>Subjects received a single oral dose of 60 mg of Metadate CD (Methylphenidate HCl given as one 60 mg capsule)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Patrick Martin, M.D.</name_or_title>
      <organization>Shire Pharmaceutical</organization>
      <email>pmartin@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

